Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

BACKGROUND: Single-agent pembrolizumab treatment of hormone receptor-positive metastatic breast cancer (MBC) has demonstrated modest clinical responses. Little is known about potential biomarkers or mechanisms of response to immune checkpoint inhibitors (ICIs) in patients with HR+ MBC. The present s...

Descripción completa

Detalles Bibliográficos
Autores principales: Egelston, Colt, Guo, Weihua, Yost, Susan, Lee, Jin Sun, Rose, David, Avalos, Christian, Ye, Jian, Frankel, Paul, Schmolze, Daniel, Waisman, James, Lee, Peter, Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993344/
https://www.ncbi.nlm.nih.gov/pubmed/33757987
http://dx.doi.org/10.1136/jitc-2020-002084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993344/
https://www.ncbi.nlm.nih.gov/pubmed/33757987
http://dx.doi.org/10.1136/jitc-2020-002084

Ejemplares similares